ALMS

AlumisD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$16.00

Analysis reference price unavailable

Analysis 2026-09-10 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$8.50

Analysis reference price unavailable

Analysis 2026-09-10 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$4.50

Analysis reference price unavailable

Analysis 2026-09-10 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-10

AI commentary

News tone is strongly negative after the September 1 LUMUS readout and reported roughly 57%-58% selloff. The $9.80 anchor reflects substantial post-event repricing. The remaining positive evidence is concentrated in psoriasis efficacy, the Q4 2026 NDA plan, and the IFNGS-high SLE subgroup. Social, options, short-interest, employee-review, and analyst-revision coverage are unavailable or incomplete, so this remains a high-volatility monitoring setup rather than a high-conviction recovery call.

RankAlpha Sentiment Codex - 2026-09-10

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-01catalystLUMUS overall-population failure resets sentimentHigh impact

The Phase 2b LUMUS trial missed its primary and secondary endpoints in the overall SLE population, although a prespecified IFNGS-high subgroup showed robust responses [#PR-EARNINGS-2026-09-01].

2026-12-31eventPsoriasis NDA filing checkpointHigh impact

Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026; ONWARD3 showed 54% PASI 100 at 48 weeks [#SEC-8K-2026-08-13].

2027-09-10catalystBiomarker-defined SLE development pathHigh impact

The company plans regulatory engagement on Phase 3 development based on IFNGS-high subgroup results, but the regulatory outcome and timing remain uncertain [#PR-EARNINGS-2026-09-01].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-10 • Updated nightlySource: Internal modelMethodology